Stockscreener 앱 받기
49.14
4.64%
2.18
시장 영업 전:
49.10
-0.04
-0.08%
Tempus Ai Inc 주식(TEM)의 최신 뉴스
Tempus AI Inc. (TEM) Touted as a Buy Amid Focus on Healthcare Opportunities - Insider Monkey
Promising Artificial Intelligence Stocks To Follow NowMarch 23rd - MarketBeat
Tempus AI's Diagnostics and Data Arms Drive Long-Term Growth Story - The Globe and Mail
Best Artificial Intelligence Stocks Worth WatchingMarch 22nd - MarketBeat
Top Artificial Intelligence Stocks To ResearchMarch 21st - MarketBeat
Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape? - TradingView
Market Moves: What is the next catalyst for Tempus AI Inc2026 Price Momentum & Daily Profit Focused Stock Screening - baoquankhu1.vn
HC Wainwright raises Tempus AI (TEM) price target to $95 - MSN
H.C. Wainwright Raises Tempus AI (TEM) Price Target to $95 - Insider Monkey
Top Artificial Intelligence Stocks To ConsiderMarch 20th - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
10 Best New AI Stocks to Buy - Insider Monkey
Artificial Intelligence Stocks To ConsiderMarch 19th - MarketBeat
JPMorgan lowers Tempus AI (TEM) PT to $80, maintains neutral rating - MSN
Mizuho initiates coverage of Tempus AI (TEM) with outperform recommendation - MSN
3 MedTech stocks poised to gain in 2026 from the AI boom - MSN
Tempus AI Pediatric Leukemia Registry Deepens Oncology Data And Patient Reach - Yahoo Finance Singapore
Tempus AI, Inc. (TEM) announces strategic deal with Merck to fast-track AI-driven precision medicine - MSN
Is It Time To Reassess Tempus AI (TEM) After Recent Share Price Weakness? - Yahoo Finance
Promising Artificial Intelligence Stocks To Keep An Eye OnMarch 17th - MarketBeat
Is Tempus AI (TEM) The Best AI Healthcare Stock in Cathie Wood’s Portfolio? - Insider Monkey
Tempus and Blood Cancer United announce collaboration to develop one of the largest pediatric acute myeloid leukemia Real-World Data registries - marketscreener.com
Tempus and Blood Cancer United® Announce Collaboration to Develop One Of the Largest Pediatric Acute Myeloid Leukemia Real-World Data Registries - The AI Journal
Best Artificial Intelligence Stocks To Add to Your WatchlistMarch 16th - MarketBeat
Tempus AI Advances Clinical Applications and Healthcare Software - TradingView
Bamco Inc. NY Increases Stake in Tempus AI, Inc. - National Today
Tempus AI, Inc. $TEM Shares Bought by Bamco Inc. NY - MarketBeat
Why Tempus AI, Inc. (TEM) Went Down On Wednesday - MSN
Cathie Wood buys $2 million of tumbling AI stock - MSN
Best Artificial Intelligence Stocks To Follow NowMarch 15th - MarketBeat
Clear Street Group Inc. Acquires Stake in Tempus AI - National Today
Casdin Capital LLC Purchases Shares of 294,127 Tempus AI, Inc. $TEM - MarketBeat
Clear Street Group Inc. Acquires Shares of 716,406 Tempus AI, Inc. $TEM - MarketBeat
Artificial Intelligence Stocks Worth WatchingMarch 14th - MarketBeat
Tempus AI falls despite Q4 beats, 2026 revenue guidance above consensus - MSN
Tempus AI price target lowered to $80 from $85 at JPMorgan - MSN
Top Artificial Intelligence Stocks To Watch NowMarch 13th - MarketBeat
Tempus AI, Inc. $TEM Shares Acquired by Landscape Capital Management L.L.C. - MarketBeat
Tempus AI, Inc. Class A Trade Ideas — BX:TEM - TradingView
Tempus AI, Inc. $TEM Shares Acquired by BNP Paribas Financial Markets - MarketBeat
Tempus AI’s Ambry Genetics Leads with Validated 99.5% Accurate Hereditary Cancer Risk Assessment Tool - MSN
Assessing Tempus AI (TEM) Valuation As New Oncology Study Highlights Clinical Impact Of Its AI Platform - simplywall.st
Tempus AI Inc (TEM) Shares Down 5.14% on Mar 12 - GuruFocus
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics - Yahoo Finance
First Trust Advisors LP Has $47.63 Million Position in Tempus AI, Inc. $TEM - MarketBeat
Cathie Wood’s ARK sells LY Corp stock, buys Tempus AI - Investing.com
Tempus AI Earnings Call Highlights Strong Growth Path - The Globe and Mail
Tempus AI Broadens Clinical Assessment of AI-Driven Cancer Diagnostic Tools - Bitget
Promising Artificial Intelligence Stocks To Follow TodayMarch 11th - MarketBeat
Why Tempus AI Stock Is Up Wednesday?Tempus AI (NASDAQ:TEM) - Benzinga
Tempus Announces Study Highlighting the Role of Advanced Genomic Profiling Features in Identifying Clinically Actionable Findings - Business Wire
Tempus AI's (TEM) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Tempus AI: Underappreciated Oncology Platform and Data Business Poised for Reimbursement Upside and AI-Driven Growth - TipRanks
Tempus cancer study: deeper test gives 1 in 8 new treatment options - Stock Titan
Hims and Hers Expands Consumer-Focused Digital Health Platform - The Globe and Mail
2.16%
자본화:
|
볼륨(24시간):